You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: November 22, 2024

Details for Patent: 10,758,549

✉ Email this page to a colleague

« Back to Dashboard

Which drugs does patent 10,758,549 protect, and when does it expire?

Patent 10,758,549 protects OCALIVA and is included in one NDA.

This patent has thirty-three patent family members in twenty-five countries.

Summary for Patent: 10,758,549

Title:	Compositions of obeticholic acid and methods of use
Abstract:	The disclosure relates to obeticholic acid formulations with improved stability, dissolution, and/or solubility, methods of preparing the same for use and methods of treating various diseases and conditions.
Inventor(s):	Lancaster; Richard Gail (San Diego, CA), Olmstead; Kay K. (Escondido, CA), Kagihiro; Masashi (Suita, JP), Matono; Mitsuhiro (Osaka, JP), Taoka; Ikuko (Toyonaka, JP), Pruzanski; Mark (New York, NY), Shapiro; David (Rancho Santa Fe, CA), Hooshmand-Rad; Roya (San Diego, CA), Pencek; Richard (San Diego, CA), Sciacca; Cathi (San Diego, CA), Eliot; Lise (San Diego, CA), Edwards; Jeffrey (San Diego, CA), MacConell; Leigh A. (Encinitas, CA), Marmon; Tonya K. (San Diego, CA)
Assignee:	Intercept Pharmaceuticals, Inc. (New York, NY)
Application Number:	16/787,796
Patent Claim Types: see list of patent claims	Use; Composition; Dosage form;

Drugs Protected by US Patent 10,758,549

Subscribe to access the full database, or Sign Up
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Intercept Pharms Inc	OCALIVA	obeticholic acid	TABLET;ORAL	207999-001	May 27, 2016		RX	Yes	No	⤷ Sign Up	⤷ Sign Up				TREATMENT OF PRIMARY BILIARY CHOLANGITIS (PBC) IN COMBINATION WITH URSODEOXYCHOLIC ACID (UDCA) IN ADULTS WITH AN INADEQUATE RESPONSE TO UDCA, OR AS MONOTHERAPY IN ADULTS UNABLE TO TOLERATE UDCA	⤷ Sign Up
Intercept Pharms Inc	OCALIVA	obeticholic acid	TABLET;ORAL	207999-002	May 27, 2016		RX	Yes	Yes	⤷ Sign Up	⤷ Sign Up				TREATMENT OF PRIMARY BILIARY CHOLANGITIS (PBC) IN COMBINATION WITH URSODEOXYCHOLIC ACID (UDCA) IN ADULTS WITH AN INADEQUATE RESPONSE TO UDCA, OR AS MONOTHERAPY IN ADULTS UNABLE TO TOLERATE UDCA	⤷ Sign Up
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Patented / Exclusive Use	>Submissiondate

International Family Members for US Patent 10,758,549

Subscribe to access the full database, or Sign Up
Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Argentina	104427	⤷ Sign Up
Australia	2016255045	⤷ Sign Up
Australia	2020205315	⤷ Sign Up
Brazil	112017023161	⤷ Sign Up
>Country	>Patent Number	>Estimated Expiration	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.